UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

~~Pursuant~~PURSUANT toTO ~~Section~~SECTION 13 orOR 15(d) of

~~The~~OF ~~Securities~~THE ~~Exchange~~SECURITIES ~~Act~~EXCHANGE ofACT OF 1934

Date of Report (Date of earliest event reported): ~~July~~August 112, 2016

~~ROCK~~Rock ~~CREEK~~Creek ~~PHARMACEUTICALS~~Pharmaceuticals, ~~INC~~Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	000-15324 (Commission File Number)	52-1402131 (IRS Employer Identification No.)
Delaware		000-15324	52-1402131
	2040 Whitfield Avenue, Suite 300 Sarasota, Florida 34243 (Address of principal executive offices, including zip code) 844-727-0727 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report)
(State or other jurisdiction of incorporation)		(Commission File Number)	(IRS Employer Identification No.)

2040 Whitfield Avenue, Suite 300

Sarasota, Florida 34243

(Address of principal executive offices, including zip code)

844-727-0727

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.0207. ~~Departure~~Submission of ~~Directors~~Matters orto ~~Certain~~a ~~Officers;~~Vote ~~Election~~ of ~~Directors;~~Security ~~Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Holders.

On ~~July~~August ~~1 and July 5~~12, 2016, ~~respectively,~~the ~~Mr.~~Company ~~Scott~~held ~~Sensenbrenner~~its annual ~~and~~meeting Msof stockholders. ~~Sunitha~~The ~~Chundru~~Company ~~Samuel~~previously ~~resigned~~filed asthe ~~directors~~Proxy ofStatement ~~Rock~~and ~~Creek~~related ~~Pharmaceuticals,~~materials pertaining to the Annual ~~Inc.~~Meeting (with the ~~“Company”)~~SEC. ~~Neither~~On ofthe ~~their~~record ~~resignations~~date ~~were~~of ~~due~~July to22, a2016, ~~disagreement~~there ~~with~~were ~~the~~170,444,758 ~~Company~~shares onof ~~any~~Common ~~matter~~Stock ~~relating~~outstanding and entitled to ~~the~~vote ~~Company’s~~at ~~operations,~~the ~~policies,~~Annual ~~or practices~~Meeting.

~~SIGNATURE~~Proposal 1: Election of Directors

~~Pursuant~~Three tonominees ~~the~~for ~~requirements of~~ the ~~Securities~~Board ~~Exchange Act~~ of ~~1934,~~Directors were ~~the~~elected ~~registrant has duly caused this report~~ to beserve ~~signed~~for onone-year ~~its~~terms. ~~behalf~~The bytabulation ~~the~~of ~~undersigned hereunto~~votes ~~duly~~was ~~authorized.~~as follows:

ROCK CREEK PHARMACEUTICALS, INC. By: /s/ Michael J. Mullan Michael J. Mullan Chairman of the Board and Chief Executive Officer

Nominee	Votes For	Votes Withheld

Lee M. Canaan	37,956,908	4,123,314

Michael John Mullan	37,911,618	4,168,604

Robert W. Scannell	38,025,629	4,054,593

~~Date~~Proposal 2: ~~July~~A 8proposal to approve an amendment (in the event it is deemed by the Company’s Board of Directors to be advisable) to the Company’s Tenth Amended and Restated Certificate of Incorporation, ~~2016~~as amended, to effect a reverse stock split of the Company’s issued and outstanding common stock

The Company’s proposal to approve an amendment (in the event it is deemed by the Company’s Board of Directors to be advisable) to the Company’s Tenth Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding common stock at a ratio within the range of one-for-fifty (1:50) to one-for-two hundred (1:200), as determined by the Board of Directors, was approved as set forth below:

For	Against	Abstain
95,790,971	42,532,084	1,919,301

Proposal 3: Approval of the Company’s 2016 Omnibus Incentive Plan

The Company’s proposal to approve the Company’s 2016 Omnibus Incentive Plan was approved as set forth below:

For	Against	Abstain	Broker Non-Votes
30,275,080	10,074,178	1,730,964	96,162,134

Proposal 4: Ratification of the Appointment of Independent Auditor

The appointment of Cherry Bekaert LLP as the Company’s independent auditor to audit the Company’s 2016 financial statements was ratified as set forth below:

For	Against	Abstain
134,507,671	3,078,932	2,655,753

Proposal 5: Advisory Vote on Executive Compensation

An advisory resolution on the compensation of the Company’s named executive officers was ratified as set forth below:

For	Against	Abstain	Broker Non-Votes
45,528,252	8,943,611	2,894,316	96,100,877

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ROCK CREEK PHARMACEUTICALS, INC.

Date: August 17, 2016

	By:	/s/ William L. McMahon
	Name:	William L. McMahon
	Title:	Chief Financial Officer

Filing Compare · ROCK CREEK PHARMACEUTICALS, INC.